RxDoctor Payments Data

Howard Rothman, MD

Cardiovascular Disease · Fort Lee, NJNPI 1134125941

Payments from drug & device makers

$3,193in general payments, 2019–2025

Across 217 payments — averaging $14.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$338
  • Novartis$231
  • Pfizer$191
  • Cvrx, Inc.$190
  • Amarin Pharma, Inc.$166
  • Novo Nordisk$155
  • plus $2K from 33 others

What the payments were for

  • Food & beverage$3,16399%
  • Education$301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,193 in reported general payments places this provider in the 50th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$52,685
Medicare patients
526
Services billed
1,032

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban135$192,103
EntrestoSacubitril/Valsartan27$38,474
Repatha SureclickEvolocumab20$18,750
Praluent PenAlirocumab19$16,866
JardianceEmpagliflozin22$15,978
EdarbiAzilsartan Medoxomil21$8,705
RestasisCyclosporine12$7,795
Atorvastatin Calcium377$4,709
Ranolazine ErRanolazine13$3,450
Metoprolol Succinate170$3,376
Nebivolol Hcl36$3,034
Rosuvastatin Calcium120$2,434
Ezetimibe-SimvastatinEzetimibe/Simvastatin15$2,279
Ezetimibe84$2,164
Omega-3 Acid Ethyl Esters19$2,138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$191$192,103135 claims
NovartisEntresto$231$38,47427 claims
Boehringer IngelheimJardiance$132$15,97822 claims
Arbor Pharmaceuticals, Inc.Edarbi$52$8,70521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Fort Lee

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →